IZTC
NASDAQInvizyne Technologies Inc.
Invizyne Technologies Inc. (IZTC) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. There were no new wire items for IZTC in the last 30 days. The most recent was published Feb 12, 2025.
Latest news
25 items- PRRebranding Invizyne to eXoZymes Signifies a Sustainable Paradigm Shift in Chemical Production Leveraging AI-Engineered EnzymesRebranding Invizyne Technologies, Inc to eXoZymes Inc.Changing NASDAQ ticker from IZTC to EXOZIntroducing but not trademarking "exozymes" as a new scientific nomenclature Monrovia, California, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc. - a pioneer of AI-engineered enzymes that can sustainably transform feedstock into essential chemicals, medicines, and biofuels, announced a corporate name change to eXoZymes, Inc. ("eXoZymes") and that its common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol of "EXOZ" effective before the market open. No action is required by existing shareholders with respect to the name and ticker symbol c
- SECInvizyne Technologies Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - EXOZYMES INC. (0002010788) (Filer)
- PRInvizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker SymbolMonrovia, CA, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc., (NASDAQ:IZTC) ("Invizyne"), a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, announced a corporate name change to eXoZymes, Inc. ("eXoZymes") and an application for a new ticker symbol. The company expects trading under the new ticker symbol of "EXOZ" to begin on February 12, 2025, subject to final approvals. In connection with the corporate name change, Company branding, including the corporate website, will be updated accordingly. No action is required by existing shareholders with respect to the name and
- INSIDERChief Executive Officer Heltzen Michael bought $20,345 worth of shares (1,888 units at $10.78), increasing direct ownership by 95% to 3,872 units (SEC Form 4)4 - Invizyne Technologies Inc (0002010788) (Issuer)
- INSIDERChief Executive Officer Heltzen Michael bought $22,022 worth of shares (1,984 units at $11.10) (SEC Form 4)4 - Invizyne Technologies Inc (0002010788) (Issuer)
- INSIDERSEC Form 3 filed by new insider Bell Lon E3 - Invizyne Technologies Inc (0002010788) (Issuer)
- PRInvizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel CapabilitiesMonrovia, CA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Today, Invizyne Technologies, Inc., (NASDAQ:IZTC) ("Invizyne"), a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, announced it was awarded a $2 million project to enable enzyme production for cell-free biomanufacturing of sustainable aviation fuel (SAF). The project is a cost share grant from the U.S. Department of Defense's BioMADE initiative, in partnership with the University of Georgia. It is one of 17 BioMADE projects announced on October 30, 2024, to drive the scale-up and commercialization of American biomanufactured products. "The nex
- 13D/GSEC Form SC 13D filed by Invizyne Technologies Inc.SC 13D - Invizyne Technologies Inc (0002010788) (Subject)
- 13D/GSEC Form SC 13D filed by Invizyne Technologies Inc.SC 13D - Invizyne Technologies Inc (0002010788) (Subject)
- 13D/GSEC Form SC 13D filed by Invizyne Technologies Inc.SC 13D - Invizyne Technologies Inc (0002010788) (Subject)
- 13D/GSEC Form SC 13D filed by Invizyne Technologies Inc.SC 13D - Invizyne Technologies Inc (0002010788) (Subject)
- INSIDERVice President, Development Opgenorth Paul Hideo converted options into 2,344 shares, increasing direct ownership by 0.37% to 640,504 units (SEC Form 4)4 - Invizyne Technologies Inc (0002010788) (Issuer)
- INSIDERLarge owner Mdb Capital Holdings, Llc converted options into 122,657 shares, increasing direct ownership by 3% to 3,931,133 units (SEC Form 4)4 - Invizyne Technologies Inc (0002010788) (Issuer)
- INSIDERNew insider Digiandomenico Anthony claimed ownership of 3,808,476 shares (SEC Form 3)3 - Invizyne Technologies Inc (0002010788) (Issuer)
- INSIDERNew insider Opgenorth Paul Hideo claimed ownership of 638,160 shares (SEC Form 3)3 - Invizyne Technologies Inc (0002010788) (Issuer)
- INSIDERNew insider Korman Tyler Paz claimed ownership of 722,301 shares (SEC Form 3)3 - Invizyne Technologies Inc (0002010788) (Issuer)
- INSIDERNew insider Mdb Capital Holdings, Llc claimed ownership of 3,808,476 shares (SEC Form 3)3 - Invizyne Technologies Inc (0002010788) (Issuer)
- INSIDERNew insider Marlett Christopher A claimed ownership of 3,808,476 shares (SEC Form 3)3 - Invizyne Technologies Inc (0002010788) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lalonde James Joseph3 - Invizyne Technologies Inc (0002010788) (Issuer)
- INSIDERSEC Form 3 filed by new insider Heltzen Michael3 - Invizyne Technologies Inc (0002010788) (Issuer)
- INSIDERNew insider Hayat Mohammad claimed ownership of 155,818 shares (SEC Form 3)3 - Invizyne Technologies Inc (0002010788) (Issuer)
- INSIDERNew insider Bowie James Ulrich claimed ownership of 577,910 shares (SEC Form 3)3 - Invizyne Technologies Inc (0002010788) (Issuer)
- INSIDERSEC Form 3 filed by new insider Nawaz Fouad3 - Invizyne Technologies Inc (0002010788) (Issuer)
- SECInvizyne Technologies Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Invizyne Technologies Inc (0002010788) (Filer)
- PRInvizyne Technologies Announces Closing of Initial Public OfferingMonrovia, CA, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc., a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, today announced the closing of its initial public offering of 1,875,000 shares of its common stock at a public offering price of $8.00 per share. The shares began trading on NASDAQ under the ticker symbol "IZTC" on November 13, 2024. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $15,000,000. The Company has granted a 45-day option to the underwriter to purchase up to 2
IZTC FAQ
6 questionsWhat is the latest news on IZTC?
Quantisnow has not tracked any new filings, ratings or press releases for IZTC in the last 30 days. The most recent wire item was published on February 12, 2025.Where does IZTC stock trade?
Invizyne Technologies Inc. (IZTC) is listed on NASDAQ.What sector and industry is IZTC in?
Invizyne Technologies Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Invizyne Technologies Inc. go public?
Invizyne Technologies Inc. (IZTC) completed its IPO in 2024.What companies are similar to IZTC?
Notable peers in the same industry include AMGN (Amgen Inc.), ARGX (argenx SE), MRNA (Moderna Inc.), RVMD (Revolution Medicines Inc.), GILD (Gilead Sciences Inc.). Compare IZTC side-by-side with any of them on Quantisnow.How can I track IZTC on Quantisnow?
Quantisnow aggregates Invizyne Technologies Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IZTC to receive live email and push alerts on every new disclosure.